Pulse Biosciences stock (US73242P1030): CEO buys $295K in shares

Pulse Biosciences CEO Paul A. Laviolette acquired 15,000 shares of the company's common stock on May 11, 2026, at $19.69 per share, totaling $295,350, according to an SEC Form 4 filing. The transaction was executed through the company's at-the-market equity offering program with TD Securities (USA) LLC, during an open trading window. This increased his direct ownership to 15,846 shares. Separately, co-chairmen made ATM equity purchases totaling approximately $13.3 million, as reported on May 12, 2026 by Stock Titan as of 05/11/2026 and TradingView/Refinitiv as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Pulse Biosciences: core business model

Pulse Biosciences develops and commercializes NanoSecond Pulsed Field Ablation (nsPFA) technology for medical applications, primarily targeting cardiac arrhythmias like atrial fibrillation. The platform uses ultra-short, high-voltage electrical pulses to ablate tissue non-thermally, aiming to reduce risks associated with traditional thermal ablation methods. The company, listed on Nasdaq under ticker PLSE, focuses on advancing clinical evidence for its systems through trials and regulatory submissions.

Headquartered in the US, Pulse Biosciences operates in the medtech space with a pipeline centered on electrophysiology devices. Its technology is designed for precision and safety, appealing to electrophysiologists treating complex cardiac conditions prevalent in aging US populations.

Main revenue and product drivers for Pulse Biosciences

The company's primary revenue driver is its nsPFA Cardiac Ablation System, currently in clinical development. Key milestones include FDA approvals and trial data readouts that could enable commercialization. Pulse Biosciences generates limited revenue currently, relying on funding and partnerships while scaling manufacturing and clinical programs.

Insider confidence, as shown by recent purchases, underscores belief in upcoming catalysts like trial results or regulatory progress. On May 11, 2026, shares traded at $19.69 on Nasdaq, reflecting a market cap of approximately $1.301 billion per GuruFocus as of 05/11/2026.

Industry trends and competitive position

The cardiac ablation market is growing due to rising atrial fibrillation cases in the US, projected to affect over 12 million Americans by 2030. nsPFA represents a next-generation approach, competing with thermal technologies from leaders like Medtronic and Boston Scientific. Pulse Biosciences differentiates through non-thermal selectivity, potentially lowering complication rates.

Why Pulse Biosciences matters for US investors

As a Nasdaq-listed medtech innovator, Pulse Biosciences offers US investors exposure to high-growth electrophysiology. Its nsPFA platform addresses unmet needs in a $5B+ US ablation market, with relevance amplified by domestic headquarters and FDA pathway focus.

Conclusion

Recent insider buying by Pulse Biosciences' CEO and co-chairmen signals internal optimism amid clinical progress in nsPFA technology. With shares at $19.69 on May 11, 2026, the stock reflects market attention to potential catalysts in cardiac ablation. US investors track such moves alongside trial updates and regulatory news for context in the competitive medtech landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.